| Perfluorooctanoic acid (PFOA) exposure, DNA methylation patterns, and renal cell carcinoma |
Charles Breeze |
National Cancer Institute |
PLCO |
Jan 19, 2023 |
2022-0036 |
| Performance evaluation and generalisability of an AI algorithm for lung cancer detection |
Lizzie Barclay |
Annalise-AI Pty Ltd |
PLCO |
May 30, 2023 |
PLCOI-1234 |
| Performance Evaluation of Colorectal Cancer Diagnosis Classification using Machine Learning Algorithms. |
HYUNJIN KWON |
Open Convergence Lab |
PLCO |
Sep 28, 2018 |
PLCO-399 |
| Personalised lung cancer treatment through outcome predictions and patient stratification |
Charles-Antoine Collins Fekete |
University College London |
NLST |
Feb 16, 2022 |
NLST-881 |
| Personalized Dynamic Risk-based Lung Cancer Screening |
Sylvia Plevritis |
Stanford University |
NLST |
Aug 30, 2018 |
NLST-438 |
| Personalized Medicine: A New Paradigm of Decision Support for Pulmonary Nodules Using the National Lung Screening Trial Dataset |
James Morrison |
University of Maryland |
NLST |
Sep 12, 2013 |
NLST-35 |
| Personalized Risk Information in Cost Effectiveness Studies (PRICES) |
David Kent |
Tufts Medical Center |
NLST |
Jan 10, 2014 |
NLST-47 |
| Personalizing colorectal treatment strategies through machine learning |
Jean-Emmanuel Bibault |
Stanford University |
PLCO |
Feb 27, 2020 |
PLCO-592 |
| Personalizing Lung Cancer Screening for Smokers with Comorbidities |
Minal Kale |
Icahn School of Medicine at Mount Sinai |
PLCO |
Feb 7, 2020 |
PLCO-578 |
| Personalizing screening intervals for lung cancer screening using artificial intelligence |
Scott Adams |
University of Saskatchewan |
NLST |
May 30, 2023 |
NLST-1064 |
| PFAS predictive modeling using case control study data |
David Madigan |
Northeastern University |
PLCO |
Jan 6, 2025 |
PLCO-1756 |
| Phase 3 validation of a serum miRNA neural network for early detection of ovarian cancer |
Kevin Elias |
Brigham and Women's Hospital |
PLCO |
Aug 3, 2017 |
2017-0023 |
| Phase 3 validation of early detection biomarker panel for pancreatic cancer |
Ann Oberg |
Mayo Clinic |
PLCO |
Feb 2, 2017 |
2016-0041 |
| Phase III validation using PLCO specimens of a consensus panel of ovarian cancer biomarkers developed by SPORE/EDRN investigators |
Daniel W. Cramer |
Brigham and Women's Hospital / Harvard Medical School |
PLCO |
Aug 17, 2005 |
2005-0009 |
| Phase III validation using PLCO specimens of a consensus panel of ovarian cancer biomarkers developed by SPORE/EDRN investigators: Study 4: Validation using PLCO serial specimens of PLCO Ovarian Cance |
Nicole Urban |
Fred Hutchinson Cancer Research Center |
PLCO |
Jun 19, 2009 |
2009-0504 |
| Physical activity, PSA levels, and screen-detected prostate cancers. |
Yelena Tarasenko |
Georgia Southern University |
PLCO |
Oct 23, 2018 |
PLCO-415 |
| Phytoestrogen intake and risk of advanced breast cancer |
Michael Reger |
University of Notre Dame |
PLCO |
Aug 9, 2024 |
PLCO-1642 |
| Phytoestrogen intake and the risk of total and advanced colorectal cancer |
Michael Reger |
Ferris State University |
PLCO |
Mar 8, 2018 |
PLCO-353 |
| Phytoestrogen intake and the risk of total and advanced prostate cancer |
Michael Reger |
Indiana University - Indianapolis |
PLCO |
Oct 17, 2013 |
PLCO-48 |
| Pilot Study for serum and plasma samples |
Camargo Costanza |
NIH |
PLCO |
Apr 3, 2025 |
2025-9010 |
